Second-line chemotherapy for advanced pancreatic cancer: Which is the best option?

Giuseppe Aprile, Francesca V. Negri, Francesco Giuliani, Elisa De Carlo, Davide Melisi, Francesca Simionato, Nicola Silvestris, Oronzo Brunetti, Francesco Leone, Donatella Marino, Daniele Santini, Emanuela Dell'Aquila, Tea Zeppola, Marco Puzzoni, Mario Scartozzi

Research output: Contribution to journalReview article

9 Citations (Scopus)

Abstract

Despite recent biological insight and therapeutic advances, the prognosis of advanced pancreatic cancer still remains poor. For more than 15 years, gemcitabine monotherapy has been the cornerstone of first-line treatment. Recently, prospective randomized trials have shown that novel upfront combination regimens tested in prospective randomized trials have resulted in improved patients' outcome increasing the proportion of putative candidate to second-line therapy. There is no definite standard of care after disease progression. A novel formulation in which irinotecan is encapsulated into liposomal-based nanoparticles may increase the efficacy of the drug without incrementing its toxicity. NAPOLI-1 was the first randomized trial to compare nanoliposomal irinotecan and fluorouracil-leucovorin (5-FU/LV) to 5-FU/LV alone after a gemcitabine-based chemotherapy. This review focuses on the current data for the management of second-line treatment for metastatic pancreatic adenocarcinoma, presents the most interesting ongoing clinical trials and illustrates the biologically-driven future options beyond disease progression.

Original languageEnglish
Pages (from-to)1-12
Number of pages12
JournalCritical Reviews in Oncology/Hematology
Volume115
DOIs
Publication statusPublished - Jul 1 2017

Fingerprint

irinotecan
gemcitabine
Pancreatic Neoplasms
Fluorouracil
Drug Therapy
Disease Progression
Leucovorin
Therapeutics
Standard of Care
Nanoparticles
Adenocarcinoma
Clinical Trials
Pharmaceutical Preparations

Keywords

  • Advanced pancreatic adenocarcinoma
  • Clinical trials
  • Nanoliposomal irinotecan
  • Second-line treatment

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Geriatrics and Gerontology

Cite this

Second-line chemotherapy for advanced pancreatic cancer : Which is the best option? / Aprile, Giuseppe; Negri, Francesca V.; Giuliani, Francesco; De Carlo, Elisa; Melisi, Davide; Simionato, Francesca; Silvestris, Nicola; Brunetti, Oronzo; Leone, Francesco; Marino, Donatella; Santini, Daniele; Dell'Aquila, Emanuela; Zeppola, Tea; Puzzoni, Marco; Scartozzi, Mario.

In: Critical Reviews in Oncology/Hematology, Vol. 115, 01.07.2017, p. 1-12.

Research output: Contribution to journalReview article

Aprile, G, Negri, FV, Giuliani, F, De Carlo, E, Melisi, D, Simionato, F, Silvestris, N, Brunetti, O, Leone, F, Marino, D, Santini, D, Dell'Aquila, E, Zeppola, T, Puzzoni, M & Scartozzi, M 2017, 'Second-line chemotherapy for advanced pancreatic cancer: Which is the best option?', Critical Reviews in Oncology/Hematology, vol. 115, pp. 1-12. https://doi.org/10.1016/j.critrevonc.2017.03.025
Aprile, Giuseppe ; Negri, Francesca V. ; Giuliani, Francesco ; De Carlo, Elisa ; Melisi, Davide ; Simionato, Francesca ; Silvestris, Nicola ; Brunetti, Oronzo ; Leone, Francesco ; Marino, Donatella ; Santini, Daniele ; Dell'Aquila, Emanuela ; Zeppola, Tea ; Puzzoni, Marco ; Scartozzi, Mario. / Second-line chemotherapy for advanced pancreatic cancer : Which is the best option?. In: Critical Reviews in Oncology/Hematology. 2017 ; Vol. 115. pp. 1-12.
@article{7ace2df9ad32454c9bb2c2b8ac33d483,
title = "Second-line chemotherapy for advanced pancreatic cancer: Which is the best option?",
abstract = "Despite recent biological insight and therapeutic advances, the prognosis of advanced pancreatic cancer still remains poor. For more than 15 years, gemcitabine monotherapy has been the cornerstone of first-line treatment. Recently, prospective randomized trials have shown that novel upfront combination regimens tested in prospective randomized trials have resulted in improved patients' outcome increasing the proportion of putative candidate to second-line therapy. There is no definite standard of care after disease progression. A novel formulation in which irinotecan is encapsulated into liposomal-based nanoparticles may increase the efficacy of the drug without incrementing its toxicity. NAPOLI-1 was the first randomized trial to compare nanoliposomal irinotecan and fluorouracil-leucovorin (5-FU/LV) to 5-FU/LV alone after a gemcitabine-based chemotherapy. This review focuses on the current data for the management of second-line treatment for metastatic pancreatic adenocarcinoma, presents the most interesting ongoing clinical trials and illustrates the biologically-driven future options beyond disease progression.",
keywords = "Advanced pancreatic adenocarcinoma, Clinical trials, Nanoliposomal irinotecan, Second-line treatment",
author = "Giuseppe Aprile and Negri, {Francesca V.} and Francesco Giuliani and {De Carlo}, Elisa and Davide Melisi and Francesca Simionato and Nicola Silvestris and Oronzo Brunetti and Francesco Leone and Donatella Marino and Daniele Santini and Emanuela Dell'Aquila and Tea Zeppola and Marco Puzzoni and Mario Scartozzi",
year = "2017",
month = "7",
day = "1",
doi = "10.1016/j.critrevonc.2017.03.025",
language = "English",
volume = "115",
pages = "1--12",
journal = "Critical Reviews in Oncology/Hematology",
issn = "1040-8428",
publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - Second-line chemotherapy for advanced pancreatic cancer

T2 - Which is the best option?

AU - Aprile, Giuseppe

AU - Negri, Francesca V.

AU - Giuliani, Francesco

AU - De Carlo, Elisa

AU - Melisi, Davide

AU - Simionato, Francesca

AU - Silvestris, Nicola

AU - Brunetti, Oronzo

AU - Leone, Francesco

AU - Marino, Donatella

AU - Santini, Daniele

AU - Dell'Aquila, Emanuela

AU - Zeppola, Tea

AU - Puzzoni, Marco

AU - Scartozzi, Mario

PY - 2017/7/1

Y1 - 2017/7/1

N2 - Despite recent biological insight and therapeutic advances, the prognosis of advanced pancreatic cancer still remains poor. For more than 15 years, gemcitabine monotherapy has been the cornerstone of first-line treatment. Recently, prospective randomized trials have shown that novel upfront combination regimens tested in prospective randomized trials have resulted in improved patients' outcome increasing the proportion of putative candidate to second-line therapy. There is no definite standard of care after disease progression. A novel formulation in which irinotecan is encapsulated into liposomal-based nanoparticles may increase the efficacy of the drug without incrementing its toxicity. NAPOLI-1 was the first randomized trial to compare nanoliposomal irinotecan and fluorouracil-leucovorin (5-FU/LV) to 5-FU/LV alone after a gemcitabine-based chemotherapy. This review focuses on the current data for the management of second-line treatment for metastatic pancreatic adenocarcinoma, presents the most interesting ongoing clinical trials and illustrates the biologically-driven future options beyond disease progression.

AB - Despite recent biological insight and therapeutic advances, the prognosis of advanced pancreatic cancer still remains poor. For more than 15 years, gemcitabine monotherapy has been the cornerstone of first-line treatment. Recently, prospective randomized trials have shown that novel upfront combination regimens tested in prospective randomized trials have resulted in improved patients' outcome increasing the proportion of putative candidate to second-line therapy. There is no definite standard of care after disease progression. A novel formulation in which irinotecan is encapsulated into liposomal-based nanoparticles may increase the efficacy of the drug without incrementing its toxicity. NAPOLI-1 was the first randomized trial to compare nanoliposomal irinotecan and fluorouracil-leucovorin (5-FU/LV) to 5-FU/LV alone after a gemcitabine-based chemotherapy. This review focuses on the current data for the management of second-line treatment for metastatic pancreatic adenocarcinoma, presents the most interesting ongoing clinical trials and illustrates the biologically-driven future options beyond disease progression.

KW - Advanced pancreatic adenocarcinoma

KW - Clinical trials

KW - Nanoliposomal irinotecan

KW - Second-line treatment

UR - http://www.scopus.com/inward/record.url?scp=85024834271&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85024834271&partnerID=8YFLogxK

U2 - 10.1016/j.critrevonc.2017.03.025

DO - 10.1016/j.critrevonc.2017.03.025

M3 - Review article

C2 - 28602164

AN - SCOPUS:85024834271

VL - 115

SP - 1

EP - 12

JO - Critical Reviews in Oncology/Hematology

JF - Critical Reviews in Oncology/Hematology

SN - 1040-8428

ER -